Until 25th May 2020
all Medtech products that are admitted in Switzerland for the sale can be
distributed also in the EU.
However, currently a
new treaty is negotiated by Switzerland and the EU Joint Committee in that
In case the treaty is
not going to be concluded between Switzerland and the EU, all Medtech
companies based in Switzerland are considered as not being anymore part of the
EU. Indeed this treaty hangs by a
the latest developments of the Swiss-EU negotiations concerning the
Institutional Agreement and the Mutual Recognition Agreement (MRA),
Swiss Medtech companies should be preparing for the case in which MRA would
no longer apply to the medical devices after 26th May 2020.
On November 15, in Lugano we have been honored to host the annual Tax Forum, which represents for PwC the main tax event in the Ticino area. This year we had the pleasure to host, as guest speaker, the Federal Councilor Ignazio Cassis, head of the Federal Department of Foreign Affairs.
Do you face troubles in order to be up to
date with all the required legislation changes in various countries in the
Regulatory Pharma & Life Sciences field AND combine it with your supply
chain and tax strategy?
I am happy to inform you that we have recently
launched our Pharma & Life Sciences Regulatory Radar, to strive to assist
you in that regard.
Recently you received a lot information related to Brexit. The key question in that regard: what is the next most favorable step for your Pharma and Life Sciences business? The center of the discussion should still be the handling of your supply chain.
Please find hereinafter some inputs in that regard from an UK, Ireland and Swiss perspective for your convenience:
As you may already gathered through the press the referendum for the Swiss Tax Bill and AHV-Financing (Steuervorlage und AHV-Finanzierung – STAF) has been launched with success.
The respective popular vote will take place in spring, i.e. on 19 May 2019.
A lot of pharma and life sciences companies are currently dealing with the question what will STAF mean for them.
Introduction of patent box – mandatory at cantonal level
Introduction of the special deduction for R&D costs – optional for the cantons (this deduction may not exceed 50% of the relevant R&D expenditure in Switzerland)
Tax advantages for income from patents/intellectual rights are intended to promote research and development activities and corresponding value creation. The legislation text defines which patents or comparable rights qualify for patent box taxation. In accordance with the international OECD standard, the Nexus approach will apply either by patent, by product or by product family.
For further details please contact Armin Marti or me via the usual way.
I am pleased to invite you to our Webinar on Precision Medicine and Accurate Indirect Tax
During this digital presentation our panel of experts will give you an overview of possible indirect tax implications within the pharma sector. This panel consists of many tax specialists of the pharmaceutical sector and PwC’s international indirect tax experts. Experts, who are dedicated to the pharmaceutical industry.
I will use my time slot to discuss the implications for Switzerland including which countries will be covered.
You will have the opportunity to exchange your experiences and views on the issue with other international leaders.